Comment on CMS-2026-1256-0002
American Society of EchocardiographyOpposeAdvocacy
Summary: The American Society of Echocardiography (ASE) opposes the proposed elimination of the alternative New Technology Add-on Payment (NTAP) pathway for FDA Breakthrough Device Designation technologies. They argue that removing this pathway would impair patient access to innovative cardiovascular technologies and request that CMS maintain the existing bridge between FDA recognition and hospital reimbursement.
Please see comments from the American Society of Echocardiography attached.